ClinicalTrials.gg
Not yet recruitingNCT07777029SC-METH-CESUpdated Aug 20, 2026

Subcutaneous Methadone for Cesarean Analgesia: a Non Inferiority Study Using QoR-10

An interventional study of Methadone 0.15 mg/kg and morphine in Cesarean Section Pain, sponsored by Clinica Alemana de Santiago. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Clinica Alemana de Santiago · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing methadone in Pain — 3 open to participants now, 3 under way, none of them phase 3. Methadone · Pain.

Planned enrollment
5th of 29
128 · median 40
Started
2026
the only one that year
No phase
6 of 29
1 open now
Registered
29th of 29
by date
Lead sponsor
1 of 29
Clinica Alemana de Santiago

Among the 29 studies testing methadone in Pain, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 6 with no phase, and was the 29th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 29 studies testing methadone in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing methadone in Pain, or all of them as a file.
02

Study summary

This study aims to evaluate whether subcutaneous methadone provides postoperative analgesia that is non-inferior to that achieved with intrathecal morphine in women undergoing cesarean delivery under neuraxial anesthesia. The primary outcome will be the quality of postoperative recovery, assessed using the QoR-10 score during the first 24 hours after surgery. Secondary outcomes will include postoperative pain intensity, opioid consumption, incidence of adverse effects, and maternal satisfaction.

This trial seeks to determine whether subcutaneous methadone could represent an alternative analgesic strategy within multimodal analgesia protocols for cesarean delivery.

Read the detailed description

Effective postoperative analgesia following cesarean delivery is a fundamental component of maternal recovery and patient satisfaction. Current international recommendations, including the most recent 2026 update from the PROSPECT Working Group, emphasize that neuraxial morphine remains the gold standard for postoperative analgesia. These guidelines also highlight the strong evidence supporting multimodal analgesia strategies, including the routine use of paracetamol and dexamethasone as adjuncts to improve analgesic outcomes and postoperative recovery.

Despite its efficacy, intrathecal morphine may be associated with dose-dependent adverse effects, such as pruritus, nausea, vomiting, and respiratory depression. For this reason, there remains ongoing clinical interest in identifying alternative analgesic strategies that provide comparable efficacy with a more favorable safety profile.

Methadone is a long-acting opioid that also exhibits N-methyl-D-aspartate (NMDA) receptor antagonist properties, which may enhance analgesia and reduce postoperative opioid requirements. There is evidence supporting its use in cesarean delivery when administered intravenously. In particular, a randomized trial demonstrated that intravenous methadone provides effective postoperative analgesia following cesarean delivery. However, other routes of administration have not been adequately evaluated in this setting.

The subcutaneous route may offer several potential advantages, including ease of administration, predictable absorption, and sustained systemic drug exposure, which could make it a practical alternative in obstetric analgesia. To date, subcutaneous methadone has not been evaluated nor directly compared with intrathecal morphine, which remains the current standard for post-cesarean analgesia.

03

Conditions studied

  • Cesarean Section Pain

Browse trials for

Keywords

  • cesarean section
  • methadone
  • intratecal morphine
  • recovery
  • maternal satisfaction
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-45 years
  • Singleton pregnancy at term (≥37 weeks of gestation)
  • Scheduled for elective cesarean delivery
  • Planned neuraxial spinal anesthesia
  • Ability to understand and complete the QoR-10 questionnaire
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Emergency cesarean delivery
  • to neuraxial anesthesia
  • Known or allergy to methadone or morphine
  • Chronic opioid use or opioid dependence
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Subcutaneous methadone

    Patients receive subcutaneous methadone for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.

    Drug: Methadone 0.15 mg/kg

  • Active comparator
    Intrathecal morphine

    Patients recieve intrathecal preservative-free morphine for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.

    Drug: morphine

Interventions

  • DrugMethadone 0.15 mg/kg

    Drug page: Methadone

    Subcutaneous methadone administered for postoperative analgesia following cesarean delivery under neuraxial anesthesia.

  • Intrathecal morphine administered during neuraxial anesthesia for postoperative analgesia following cesarean delivery.

06

What researchers measure

Primary outcomes

  1. Quality of Recovery-10 (QoR-10) score at 24 hours

    cesarean delivery. The QoR-10 is a validated patient-reported outcome measure ranging from 0 to 100, with higher scores indicating better recovery. The study is designed to assess noninferiority of subcutaneous methadone compared to intrathecal morphine using a predefined noninferiority margin of 8 points.

    Time frame: 24 hours

Secondary outcomes

  1. Postoperative pain intensity

    Pain intensity measured using a numerical rating scale (0-10) at rest and during movement.

    Time frame: Up to 24 hours after surgery

  2. Opioid consumption

    Total opioid consumtion within the first 24 hours after cesarean section, converted to morphine oral equivalents

    Time frame: Up to 24 hours after surgery

  3. adverse effects

    incidence of nausea, vomiting, pruritus, somnolence, respiratory deppresion within 24 hours

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Crowe G, Atterton B, Roofthooft E, Joshi GP, Rawal N, Wu C, Sauter AR, Bonnet MP, Lucas DN, Van de Velde M; PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy. Pain management after elective caesarean section under neuraxial anaesthesia: an updated systematic review and procedure-specific postoperative pain management (PROSPECT) recommendations. Anaesthesia. 2026 Jun;81(6):819-839. doi: 10.1111/anae.70141. Epub 2026 Feb 15. PubMed 41693258 ↗
  • Guevara J, Sanchez C, Organista-Montano J, Domingue BW, Guo N, Sultan P. Development and validation of a Spanish version of the Obstetric Quality of Recovery-10 item score (ObsQoR-10-Spanish). BJA Open. 2024 Mar 21;10:100269. doi: 10.1016/j.bjao.2024.100269. eCollection 2024 Jun. PubMed 38560622 ↗
  • Russell T, Mitchell C, Paech MJ, Pavy T. Efficacy and safety of intraoperative intravenous methadone during general anaesthesia for caesarean delivery: a retrospective case-control study. Int J Obstet Anesth. 2013 Jan;22(1):47-51. doi: 10.1016/j.ijoa.2012.10.007. Epub 2012 Dec 7. PubMed 23219678 ↗

Individual participant data

Plan to share: No — No individual participant data will be shared. The raw data will not be publicly available due to participant privacy and ethical constraints.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 20, 2026
StartEst.
Aug 21, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777029
Lead sponsor
Clinica Alemana de Santiago
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Aug 21, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

JAVIERA VARGAS, MD, MSc
Contact
jpvargasz@gmail.com
+56957383772

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion